Font Size, 'Look-Alikes' And Costs Are Top Concerns In Australian Drug Labeling Review
This article was originally published in SRA
Executive Summary
As part of a drive to get pharmaceutical companies to put clearer and more comprehensive information on their drug labels, Australia's regulatory body, the Therapeutic Goods Administration, is asking stakeholders to comment on its newly updated labeling rules, which among other things would impose a minimum font size for active substance names and require more substances to be listed on the label1.